Jiangsu Hengrui Medicine Co., Ltd.
600276
株式のランク
#548
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
株価
$6.89
時価総額
$43.94B
変化（1日）
-2.91%
変化（1年）
-24.78%
国
CN
取引 Jiangsu Hengrui Medicine Co., Ltd. (600276)
カテゴリー
Healthcare
Jiangsu Hengrui Medicine Co., Ltd.（600276）の株価履歴
終値の最高値: $6.77 （2026-10-01）
終値の最安値: $0.04 （2005-07-01）
終値の最安値: $0.04 （2005-07-01）
Jiangsu Hengrui Medicine Co., Ltd. の株価履歴（2005 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | -9.37% |
| 2025 | 33.70% |
| 2024 | 2.96% |
| 2023 | 15.17% |
| 2022 | -30.24% |
| 2021 | -37.82% |
| 2020 | 50.21% |
| 2019 | 73.88% |
| 2018 | 25.89% |
| 2017 | 85.51% |
| 2016 | 3.95% |
| 2015 | 100.95% |
| 2014 | 12.39% |
| 2013 | 42.52% |
| 2012 | 4.92% |
| 2011 | -16.03% |
| 2010 | 40.18% |
| 2009 | 61.62% |
| 2008 | -8.70% |
| 2007 | 153.91% |
| 2006 | 239.46% |
| 2005 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $171.67 | - |
DE
|
|
| $165.31 | 23.62% |
DE
|
|
| $40.45 | 43.11% |
JP
|
|
| $224.81 | 31.28% |
CH
|
|
| $18.43 | -4.03% |
IN
|
